COVID-19

How pooled cell populations helped accelerate COVID-19 vaccine development – and what that means for the therapeutics of the future.

Pfizer’s trial of a new medicine for COVID-19, produced with support from the US Department of Energy, could improve access to treatment.

We catch up with Christine Callahan from Thermo Fisher Scientific about how suppliers and customers need to reimagine their business models.

We spoke to Prateek Gadhoke, Global Head of Specialty Care Procurement at Sanofi, to ask what makes a strong supply chain.

A partnership between Gilead Sciences and Georgia State University has tested a new oral antiviral for COVID-19.

How will vaccine and therapeutic makers respond to the new SARS-CoV-2 variant?

Exploring the potential of vaccines for treatment equity.

The EMA has given the nod to Ronapreve and Regkirona, two monoclonal antibody treatments for COVID-19.

How RNA is making waves in the industry – and leading to new research projects and increased demand for new manufacturing capacities.

Setting its sights on self-amplifying RNA, AstraZeneca has signed a deal with Imperial College London spinoff VaxEquity.